The Ottawa Hospital Regional Cancer Centre, Ottawa, ON, Canada.
Crit Rev Oncol Hematol. 2013 Aug;87(2):132-9. doi: 10.1016/j.critrevonc.2012.12.010. Epub 2013 Jan 26.
Anemia in cancer patients can be a result of the underlying cancer or related to treatment. Erythropoiesis-stimulating agents (ESAs) are an important option for many patients with chemotherapy-induced anemia, but are immersed in controversy. This article aims to reconcile conflicting opinions and provide expert guidance for appropriate ESA use.
Teleconference, email, and a face-to-face meeting were used to assess ESA therapy "interpretive" data, which included two current meta-analyses, expert guidelines, and regulatory approved indications from Canada, Europe, and the USA.
Risks and benefits are associated with both red blood cell transfusions and ESA therapy, including improvements in hemoglobin levels and quality of life. ESAs have been associated with concerns regarding survival and progression of cancer, particularly when used in patients with cancer-related anemia.
Although safety concerns do exist, ESA therapy can be considered for use in patients with chemotherapy-induced anemia in accordance with Health Canada labeling.
癌症患者的贫血可能是由基础癌症引起的，也可能与治疗有关。促红细胞生成素刺激剂（ESA）是许多化疗引起贫血患者的重要选择，但存在争议。本文旨在调和相互矛盾的观点，并为 ESA 的合理应用提供专家指导。
使用电话会议、电子邮件和面对面会议评估 ESA 治疗的“解释性”数据，其中包括两项当前的荟萃分析、专家指南以及来自加拿大、欧洲和美国的监管批准适应症。
红细胞输注和 ESA 治疗都与风险和益处相关，包括血红蛋白水平和生活质量的改善。ESA 与癌症相关贫血患者的生存和癌症进展的担忧有关。
尽管存在安全问题，但根据加拿大卫生部的标签，可以考虑在化疗引起的贫血患者中使用 ESA 治疗。
